glp 1 startups glp-1 management platforms Market Overview: GLP-1 Agonists and the Obesity Market GLP-1 Receptor Agonist Market Size
Description
M.RengaG.RomaniL.et al
What is Ozempic Face
Patients who maintain regular schedules achieve 510% average body weight reduction, while irregular dosing patterns correlate with rebound weight gain and loss of metabolic benefit
A 2022 study in JAMA Network Open also reported 5.1% weight loss at three months and 9.2% at six months among patients using doses at or below 1 mg weekly
Except oral semaglutide, GLP-1 RAs are administered subcutaneously, particularly those with proven CV benefits
Featured image: K KStock on Adobe Stock Author:
